Condensed Aminodihydrothiazine Derivative & The Patents Act 1992

Factual and Procedural Background

This opinion concerns patent revocation proceedings initiated in Ireland relating to Patent No. (IE) 2 233 474, entitled "Condensed Aminodihydrothiazine Derivative," granted on 5 August 2015 and derived from a European patent. The patentee, Company A, sought a stay of the Irish proceedings pending the outcome of opposition proceedings before the European Patent Office (EPO) Technical Board of Appeal (TBA) in Munich. The revocation petition was filed by Company B on 27 October 2017, following opposition proceedings initiated at the EPO by Company B in May 2016. The pleadings in Ireland closed on 5 March 2018. Motions for discovery by both parties remain outstanding and were listed for mention at the hearing of the stay application conducted over two days in July 2018.

Legal Issues Presented

1. Whether the Irish patent revocation proceedings should be stayed pending the determination of parallel opposition proceedings before the EPO.
2. How to balance the interests of the parties in terms of commercial certainty, potential wasted costs, and court resources.
3. The extent to which interlocutory steps in the Irish proceedings should be stayed or permitted to proceed.

Arguments of the Parties

Company A's Arguments

• The hearing involves complex technical scientific matters across multiple specialist fields, requiring significant expert involvement and resources.
• There is a risk of wasted costs and court resources if proceedings continue in Ireland before the EPO opposition proceedings are finally determined, especially if the patent is revoked or amended by the EPO.
• The hearing of the Irish proceedings will likely not occur before Hilary Term 2020, making a stay appropriate.
• The launch of any competing product by Company B is several years away, with ongoing clinical trials and regulatory considerations; thus, urgency is lacking.
• Section 42(1)(g) of the Patents Act allows Company B to carry out studies and trials without infringement, reducing the need for immediate resolution in Ireland.
• There is a strong presumption in favor of granting a stay in parallel proceedings involving the EPO to avoid duplication and inconsistent decisions.
• Discovery and other interlocutory steps should be stayed to avoid wasted costs and resources.

Company B's Arguments

• Opposes the stay, asserting a pressing commercial need to obtain certainty regarding the patent's validity in Ireland, particularly due to manufacturing preparations at its intended site.
• Relies on grounds for revocation including insufficiency, lack of industrial application, and implausibility of the invention at the priority date.
• Manufacturing preparations require significant capital investment decisions to be made years before the anticipated product launch (projected for 2024-2026).
• Delay caused by a stay could have serious commercial consequences and delay patient access to a potentially life-changing treatment for Alzheimer’s disease.
• The Irish proceedings provide procedural advantages (discovery, expert cross-examination) not available at the EPO.
• Company B is prepared to seek an expedited hearing at the EPO and proposed a compromise stay limited to the trial hearing, allowing interlocutory steps to proceed.
• Company B maintains it will continue Irish proceedings even if the patent is upheld by the EPO, emphasizing the importance of early commercial certainty in Ireland.

Table of Precedents Cited

Court's Reasoning and Analysis

The court began from the established legal principle that a stay of national patent revocation proceedings pending EPO opposition proceedings is the default position, subject to a balancing exercise of competing interests. The court considered the complex and technical nature of the patent and proceedings, the likelihood of an expedited hearing at the EPO within approximately 12 months, and the significant risk of wasted costs and judicial resources if Irish proceedings progressed prematurely.

The court carefully weighed Company B’s commercial urgency against Company A’s concerns about wasted costs and resource inefficiency. Company B demonstrated a need for early commercial certainty at its intended manufacturing site, requiring capital investments and regulatory preparations years before product launch. The court acknowledged the public interest in minimizing delays to potential Alzheimer’s treatments.

However, the court found that Company B’s initial urgency claim was undercut by its own proposal to delay the Irish trial until after a likely EPO decision in November 2019. This concession diminished the force of its urgency argument. The court also noted the possibility of amendments to the patent by the EPO, which might require revisiting aspects of the Irish proceedings, increasing the risk of wasted costs.

In balancing these factors, the court distinguished between the trial hearing and interlocutory steps. While a stay of the trial was appropriate until after the anticipated EPO decision, interlocutory steps such as discovery and preparation should proceed to avoid undue delay and to keep the case ready for trial if the patent is upheld or amended.

The court gave weight to the limited duration of the expected EPO proceedings compared to prior cases, the significant chance of patent revocation or amendment, the public interest in timely access to new treatments, and the practical realities of court resources in Ireland. It also took into account that a first instance decision would provide meaningful commercial certainty despite potential appeals.

Holding and Implications

The court’s final decision was to grant a partial stay of the Irish patent revocation proceedings. Specifically, the court ordered:

• The fixing of a trial date is stayed until after 30 November 2019, pending the anticipated decision of the EPO Technical Board of Appeal.
• Interlocutory steps, including discovery, preparation of expert reports, and related pre-trial activities, are not stayed and should proceed to prepare the case for trial if necessary.
• The proceedings are to be adjourned to the Commercial List for mention on 2 December 2019.
• The parties are to be heard on costs at a later date, with an indication that costs of the motion to date may be costs in the cause.
• Motions for discovery are adjourned for mention on 8 October 2018, with encouragement for parties to attempt agreement beforehand.

Implications of this decision include a balanced approach that conserves court resources and avoids unnecessary costs while recognizing the commercial realities and public interest in timely resolution of patent validity issues. The decision does not set new precedent but reaffirms the established principles governing stays in parallel patent proceedings, adapted to the specific factual and procedural context of this case.